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Abstract
During the 20th century, deaths from a range of serious infectious diseases decreased dramatically 
due to the development of safe and effective vaccines. However, infant immunization coverage 
has increased only marginally since the 1960s, and many people remain susceptible to vaccine-
preventable diseases. “Catch-up vaccination” for age groups beyond infancy can be an attractive 
and effective means of immunizing people who were missed earlier. However, as newborn 
vaccination rates increase, catch-up vaccination becomes less attractive: the number of susceptible 
people decreases, so the cost to find and vaccinate each unvaccinated person may increase; 
additionally, the number of infected individuals decreases, so each unvaccinated person faces a 
lower risk of infection. This paper presents a general framework for determining the optimal time 
to discontinue a catch-up vaccination program. We use a cost-effectiveness framework: we 
consider the cost per quality-adjusted life year gained of catch-up vaccination efforts, as a function 
of newborn immunization rates over time and consequent disease prevalence and incidence. We 
illustrate our results with the example of hepatitis B catch-up vaccination in China. We contrast 
results from a dynamic modeling approach with an approach that ignores the impact of 
vaccination on future disease incidence. The latter approach is likely to be simpler for decision 
makers to understand and implement because of lower data requirements.
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1. Introduction
During the 20th century, deaths from a range of serious infectious diseases such as 
smallpox, measles, polio, diphtheria, pneumococcal disease, and bacterial meningitis 
decreased dramatically due to the development of safe and effective vaccines against these 
pathogens. However, infant immunization coverage has increased only marginally since the 
1960s, and many people remain susceptible to vaccine-preventable diseases.1 The World 
Health Organization (WHO) reports that almost 20% of children born in 2007 did not 
receive complete routine vaccination.2 Newborns and young children may not receive 
recommended vaccinations because they lack access to health care, face social barriers, or 
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have parents who are unaware of or unmotivated about vaccination.3 Vaccine price may also 
be an impediment, especially in the developing world.4, 5
Because infant immunization is incomplete, there may be a need for recurring annual 
campaigns to reach children missed in infancy. The WHO recommends expanding 
immunization to every eligible person, including those in age groups beyond infancy.1 Such 
“catch-up vaccination” can be an attractive and effective means of immunizing people who 
were missed earlier.6–8 Although newborn vaccination is the most cost-effective strategy for 
preventing disease,9, 10 catch-up vaccination for individuals missed by newborn vaccination 
can be highly cost-effective (e.g.,10). Many successful catch-up vaccination programs have 
been implemented around the globe, including immunization programs for measles,11, 12 
haemophilus influenza type B (which causes bacterial meningitis),13 and polio.14 An 
ongoing program in China aims to provide catch-up vaccination for hepatitis B virus to at 
least 500,000 children.8
For many vaccine-preventable diseases, newborn vaccination rates are increasing.4, 15, 16 
This affects the cost-effectiveness of catch-up vaccination: the number of susceptible 
individuals decreases, so the cost to find and vaccinate each unvaccinated person may 
increase; additionally, the number of infected individuals decreases, so each unvaccinated 
person faces a lower risk of infection. This paper presents a general framework for 
determining the optimal time to discontinue catch-up vaccination programs. We focus 
specifically on control of chronic diseases (as opposed to diseases such as influenza where 
patients either recover or die17). We consider an ongoing catch-up vaccination program 
where individuals of any given age(s) who missed newborn vaccination are vaccinated each 
year. We use a cost-effectiveness framework: we consider the cost per quality-adjusted life 
year (QALY) gained18 of catch-up vaccination efforts, as a function of newborn 
immunization rates over time and consequent disease prevalence and incidence. Much 
previous theoretical research on controlling vaccine-preventable diseases has focused on 
disease eradication.19–24 However, disease eradication can be extremely costly and, for most 
vaccine-preventable diseases, is not a realistic goal for the foreseeable future. Other studies 
focus on levels of vaccination to achieve herd immunity.25–27 However, it may still be 
valuable from a public health perspective to vaccinate even if coverage levels to achieve 
herd immunity are not possible, and it may also be valuable to vaccinate beyond levels 
required for herd immunity in order to hasten the decline in the epidemic. We thus focus on 
achieving various levels of disease control, rather than eradication, and we use cost-
effectiveness of these levels of control as our outcome measure; such a framework makes 
the implicit assumption that funds not spent on a particular vaccination program could be 
spent on another health intervention.18 Other research has examined the long-term impact of 
infection reduction for chronic diseases, but has focused on newborn vaccination only and 
has not used a cost-effectiveness framework.28–30
Many studies that evaluate the cost-effectiveness of vaccination use simple Markov cohort 
models that do not take into account the dynamics of the epidemic,10, 31–36 yet studies have 
shown that the impact of vaccination on herd immunity can be important, particularly when 
the vaccination program can affect a substantial fraction of the population.37–40 However, 
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studies of the impact of herd immunity often focus on mass infant vaccination for diseases 
such as measles and varicella that have relatively short infectious periods.38, 39
We solve the catch-up vaccination problem with an approach that captures the dynamics of 
infection transmission, and then contrast results from this approach with an approach that 
ignores the impact of vaccination on disease incidence. We allow for age dependency (as 
opposed to a homogeneous population17) to account for the fact that younger children may 
receive more benefits from the intervention and/or harms from infection. Age is often an 
important inclusion criteria for catch-up vaccination guidelines.41 Finally, unlike previous 
research which assumes constant marginal costs of immunization,19–21, 23, 24, 42, 43 we allow 
for increasing marginal costs.
In Section 2 we formulate our model. In Section 3 we focus on a single age group and ask, 
“What should our vaccination coverage goal be this year for each age group?” This can help 
establish the upper age limit at which one would want to start catch-up vaccination. In 
Section 4 we look over time and ask, “When should we stop catch-up vaccination programs 
for different age groups?” We illustrate our results in Section 5 with the example of hepatitis 
B catch-up vaccination in China. Section 6 concludes with discussion.
2. Model Formulation
We consider a population of individuals stratified by age and disease state. All notation is 
shown in Table 1. We define a set of mutually exclusive, collectively exhaustive age groups 
a = 0, 1, …, A, indexed by increasing age (where a = 0 represents newborns), and disease 
groups d ∈ D, where d = S denotes a susceptible individual, d = I denotes an infected 
individual, and d = R denotes an individual who is immune (either from vaccination or 
previous infection that has resolved itself). We consider a time horizon with discrete time 
increments t = 0, 1, …, T. We set the time increment t to be the same as the time units for 
age (e.g., years).
We consider the decision of whether to perform catch-up vaccination among eligible 
individuals in age group a > 0 in any time period t, and the fraction of such individuals xa(t) 
who should be vaccinated. We assume that , where  is the upper 
limit on the fraction of age group a that can feasibly be vaccinated. Vaccine-eligible 
individuals include all susceptible individuals as well as infected or immune individuals who 
are unaware of their disease status. Vaccine recordkeeping may be imperfect and some 
individuals who have already been vaccinated may be unaware of their protection. 
Moreover, for many catch-up vaccination programs, individuals are not tested for infection 
or immunity prior to vaccination, as such tests are too expensive. (For most vaccines, 
revaccination does not harm the patient.) Thus, infected and immune individuals may be 
unnecessarily vaccinated during a catch-up campaign. We assume that the newborn 
vaccination rate x0(t) is known and is determined exogenously.
To model the dynamics of infection transmission, we use an age-structured deterministic 
SIR (Susceptible, Infected, Recovered) epidemic model with homogeneous mixing.22 This 
model is similar to others used to predict long-term prevalence of chronic infectious 
diseases.28 (An SICR model incorporating an additional Carrier state could also be used, but 
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because the infectious state can be short, we elected to use an SIR model). In this model, the 
infection rate at time t is proportional to the number of infected and susceptible individuals, 
taking the form βS(t)I(t)/N(t), where β is the so-called “sufficient contact rate” (it is a 
function of the number of contacts per unit time, and the chance of infection transmission 
per contact), S(t) is the number of susceptible individuals, I(t) is the number of infected 
individuals, and N(t) is the total population size.22 In our age-structured model, the infection 
rate for individuals in age group a at time t is
The dynamics of the model are as follows. We distinguish between newborns (a = 0) and all 







We assume that initial compartment sizes are known for non-newborns (a > 0): Sa(0) = Sa,0, 
Ia(0) = Ia,0, Ra(0) = Ra,0. Equations (1) – (3) describe the entry of newborns into the system 
as susceptible, infected, or recovered (immune) and equations (4) – (6) describe disease 
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progression among individuals age 1 or older. Susceptible individuals (those not 
successfully vaccinated) acquire infection through contact with an infected person. 
Individuals enter the immune states either by developing natural immunity (they become 
infected and their immune system resolves the infection, with probability 1− pa, or by being 
successfully vaccinated). We assume that the vaccine has the same efficacy in preventing 
mother-to-child transmission as it has in conferring immunity to future infections, similar to 
many vaccines.44
The model is illustrated schematically in Figure 1. In any time period t, every individual in 
the population is in a compartment distinguished by age (a = 0, 1, …, A) and infection status 
(susceptible (S), Infected (I), or Immune (R)). At the end of any time period t, newborn 
children enter the population as either susceptible, infected, or immune (due to newborn 
vaccination). Additionally, at the end of the time period, susceptible newborns (who are now 
age a=1) can remain susceptible (thus entering compartment S1(t+1)), become infected 
(entering compartment I1(t+1)), become immune (due to vaccination, thus entering 
compartment (R1(t+1)), or die (thus leaving the population). Infected newborns can remain 
infected (entering compartment I1(t+1)), become immune (due to recovery from the 
infection, thus entering compartment (R1(t+1)), or die. Immune newborns can remain 
immune (entering compartment R1(t+1)) or die. Similarly, individuals of any age a progress 
to age a+1 at the end of the time period, with analogous transitions between infected, 
susceptible, and recovered compartments. All of these transitions occur for every time 
period t = 0, 1, …, T.
We solve the optimal vaccination problem by decomposing it. We first solve the problem for 
a single age group in a single time period (Section 3) and then consider the long-term 
problem of catch-up vaccination target coverage levels for different age groups over time 
and when to discontinue such efforts (Section 4).
3. Single-Period Decision Problem
3.1 Single-Period Problem
We first focus on a single time period and single age group α > 0 and ask, “What should our 
vaccination coverage goal be this year for each age group?” Answering this question can 
help determine how much effort to expend on different age groups and can determine the 
upper age limit at which one would want to institute catch-up vaccination. We assume that 
the newborn vaccination rate x0(t), t = 0, 1, …, T, is known. To determine the optimal level 
of catch-up vaccination, we use a cost-benefit analysis: we value health benefits in monetary 
terms. The value of the catch-up vaccination program equals the net present value of 
incremental health benefits generated by the vaccination program (calculated in monetary 
terms), minus the associated change in healthcare costs, minus the cost of the vaccination 
program (Drummond45 and Gold18 provide details on the appropriateness of this as a value 
measure). We assign a monetary value λ to each QALY experienced; this value represents 
the decision maker’s willingness to pay for an incremental QALY.18, 45 There is not always 
agreement on what this value of λ should be. However, the WHO suggests that a reasonable 
amount to pay for a disability-adjusted life year averted (which is slightly different from, but 
very similar to a QALY gained46, 47) is one to three times a country’s per capita GDP.48, 49
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The problem of maximizing the net present monetary benefit of vaccinating a fraction xα(0) 




The first term in (7) is the net present monetary value of total health benefits (QALYs 
experienced) in the population. The second term is the net present value of total healthcare 
costs in the population. The final term is the total cost to vaccinate a fraction xα(t) of all 
eligible individuals in age group α (those who are susceptible and those who are infected or 
immune but unaware of their disease status). We define this function as
(10)
where for simplicity we have dropped the argument t. The first term in (10) represents the 
fixed cost of the vaccination program. The second term represents the cost per person 
vaccinated; this is proportional to the number of susceptible individuals plus the number of 
infected and immune individuals who do not know their disease status. The per person 
vaccination cost comprises the constant per person cost of vaccination, cv, plus the 
incremental cost of vaccination above baseline, which is given by the function fa(xa). We 
assume that fa is a nonnegative, nondecreasing, convex function of xa; thus CVa(xa) is also a 
nonnegative, nondecreasing, convex function of xa, reflecting the possibility that per person 
costs rise as the number of people to be found and vaccinated declines.
Research on vaccine program size suggests that the average cost of vaccinating individuals 
begins to rise when vaccination coverage reaches high levels50 because the last individuals 
requiring vaccination may be very difficult to find and reach.51, 52 A systematic review 
found that average costs of vaccination programs operating from fixed facilities initially 
decline with the scale of vaccination programs because of high fixed costs, but costs may 
later increase when the programs expand outside of dense urban areas into more rural and 
remote regions.53 Another review found that the average cost per immunized child is often 
minimized at a coverage level of about 50–60% and then increases noticeably at about 80% 
population coverage.50
P1 is a complex nonlinear problem (the objective function is governed by the nonlinear 
dynamics of the epidemic, (1) – (6)). The problem can be solved using numerical methods: 
for any level of catch-up vaccination, one can use (1) – (6) to calculate Sa(t), Ia(t), and Ra(t) 
for a = 0, …, A, t = 1, …, T, and thus the objective function value. However, instantiation of 
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the model requires significant demographic and epidemiological data that decision makers 
may not have (e.g., the number of susceptible, infected, and immune individuals of each age, 
the disease sufficient contact rate for each age group, etc.). In the following section we 
develop a simple approximation of this model that can be used by decision makers more 
readily than the exact dynamic model.
3.2 Approximate Single-Period Problem
To simplify P1, we assume that future incidence (the chance that an unvaccinated, 
susceptible person acquires the infection in the future) does not depend on xα(0) (the fraction 
of individuals of a particular age α who are vaccinated this year). This will cause us to 
slightly understate the benefits of vaccination since vaccination leads to fewer susceptible 
individuals and thus decreased incidence. This assumption is likely to be reasonable for 
situations where the vaccination of a single age group in one year has little impact on 
disease prevalence in the entire population.
The only interactions between age cohorts in equations (4) – (6) are related to incidence. 
The assumption that xα(0) does not affect future incidence means that the only people 
affected by the catch-up vaccination program are those who receive vaccination. Thus, 
instead of tracking the nonlinear dynamic constraints (1) – (6) for all age groups in P1, in the 
approximate problem we need only look at differences in costs and health benefits for 
susceptible individuals in the age cohort who become immune through catch-up vaccination.
Given the above assumption, and letting Ha,d and Ca,d denote, respectively, the expected 
present value of lifetime health outcomes and health care costs for a person starting at age a 




The first term in the objective function is the net present monetary value of the health 
benefits minus changes in health care costs accruing from successfully vaccinated 
individuals. The second term is the vaccination cost. To solve P2, we must know Hα,R, Hα,S, 
Cα,R, and Cα,S. The quantities Hα,R and Cα,R can be calculated using Markov models or 
other models of health progression.10, 54 The quantities Hα,S and Cα,S depend on the future 
incidence of the disease which, in general, will change over time (i.e., ia(t) ≠ ia(t+1)). 
Equations (1) – (6) can be used to estimate incidence, or future incidence can be estimated 
more simply; in Section 3.3 we discuss several ways to estimate incidence. Given estimated 
future incidence, Markov models of infection and disease progression can be used to 
calculate Hα,S and Cα,S.
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It is straightforward to find the optimal level of vaccination , for P2. In the Appendix 
we derive and characterize this solution.
3.3. Estimating Infection Risk
In the approximate single-period problem P2, the infection risk (incidence) is a determinant 
of the expected health effects and health care costs for susceptible individuals, Hα,S and 
Cα,S. Estimates of future incidence are thus needed for solving P2.
The risk of infection for a susceptible individual of age a in time period t is
(12)
In this section we discuss four ways of estimating (12). In Section 5, we test these estimates 
with a numerical example of hepatitis B in China.
Dynamic Model—The risk of infection (12) can be determined by numerically solving the 
system of equations (1) – (6) to determine Ia(t) and Na(t) for t = 1, …, T. However, because 
such calculations may be complex (and instantiating the epidemic model requires estimation 
of many parameter values), we now discuss three simpler ways of estimating future disease 
incidence.
Constant Incidence—One simple estimate of future incidence is to assume that it is the 
same as current incidence; that is, ia(t) = ia(0) for all t. Although infant vaccination and 
catch-up vaccination efforts can decrease disease incidence over time, for a large population 
it may take many years before incidence decreases appreciably, so the estimate of constant 
incidence may be reasonable. If infant and catch-up vaccination rates are no lower than 
previous rates (with mixing patterns and other epidemiological parameters unchanged), then 
current incidence is an upper bound on future incidence.
Cut-off Estimate—Another estimate of future incidence can be obtained by assuming that 
the current age-infection distribution remains the same over time, except for assuming that 
individuals born at time 0 and afterward will not become infected (as though 100% of 
newborns are vaccinated with a 100% effective vaccine):
(13)
This estimate is similar to “cutting off” the tail of (or zeroing-out) the age-infection 
distribution corresponding to younger ages. This may be reasonable if the age-infection 
distribution is in a steady state to begin with and, except for vaccination of the young, it is 
expected that the steady-state infection distribution will continue.
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Age-out Estimate—Another estimate of future incidence can be obtained by assuming no 
new infections or resolved infections, and also assuming that individuals born at time 0 and 
afterward will not become infected (as though 100% are vaccinated with a 100% effective 
vaccine). This takes the current population of infected individuals with their current 
infection prevalence and “ages them out”. This implies, for example, that the infection 
prevalence for age a=10 at t=7 is equal to the infection prevalence for age a=3 at t=0. For 
some incurable chronic diseases, the infection reservoir can only be eliminated through 
mortality of those with the infection.55 If we assume Type I survivorship22 (everyone lives 
exactly A time units), then the cohort of infected people ages one time unit for every unit of 
time that passes. With this assumption, the annual risk of infection for a susceptible 
individual can be estimated as:
(14)
4. When to Stop Catch-Up Vaccination
We now examine the problem of when to stop catch-up vaccination in each age group a. The 
vaccination levels are denoted by a vector of values, xa (t), for all ages a > 0 and time 
periods t:
We assume that catch-up vaccination at the level determined at time 0 for each age group, 
, will be continued until it is no longer cost-effective to do so, and then no catch-up 
vaccination will be performed in that age group. Determining the optimal time to stop catch-
up vaccination for each age group a is equivalent to determining at what time t, . As 
before, the goal is to maximize the net monetary benefit of catch-up vaccination.
The problem can be written as:
(15)
s.t. (1) – (6)
(16)
(17)
This formulation allows us to consider catch-up vaccination in any subset of age groups; for 
age groups not considered for catch-up vaccination, we can set .
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We can solve P3 using numerical methods. To do so, we start at time t = 0 and determine the 
optimal fraction of each age group a to vaccinate by solving P1 (or we can solve P2 to 
obtain an approximate solution). Then, given these values, we project the dynamic model (1) 
– (6) forward one period. With the updated values of Sa(1), Ia(1), and Ra(1) for all a, we 
then determine whether to continue with the previous vaccination level for each age group a 
(i.e., whether ) or whether catch-up vaccination for age group a should be 
discontinued (i.e., ). We continue this process until we find t̃ such that  for 
all ages a > 0 or until t = T.
5. Example: Hepatitis B in China
We illustrate our models with the example of hepatitis B catch-up vaccination for children 
and adolescents in China. Approximately one-third of the world’s 350 million cases of 
hepatitis B infection occur in China,56, 57 where the disease is a generalized epidemic and an 
estimated 7.4% of the population is chronically infected.56, 58 Approximately 1% of those 
under 5 are infected, 2.5% of those between 5 and 14 are infected, and 8.5% of those 15 and 
older are infected.58 The most common routes of transmission are neonatal infection and 
horizontal transmission during early childhood.56, 59
The Chinese government recommended hepatitis B vaccination in 1992, and in 2002 the 
vaccine was made free for newborns. These policy changes helped newborn vaccination 
coverage rise from 70.7% in 1997 to 89.8% in 2003.59 However, even with recent dramatic 
increases in newborn vaccination rates, an estimated 150 million children in China are still 
unprotected from hepatitis B.4, 58 Infection in children is a particular problem because the 
younger the age at infection, the more likely it is that the infection will become chronic 
(lifelong).60 Left untreated, approximately one in four chronically infected individuals will 
die from liver disease related to hepatitis B.44, 61, 62 Because it is effective and cost-effective 
(and likely to be cost-saving10), hepatitis B catch-up vaccination for school-age children was 
made free by the government in 2009.63 At the same time, extensive public health efforts 
have led to steady increases in newborn vaccination rates across the country.4 Given the 
increases in newborn vaccination rates, when is catch-up vaccination for different age 
groups no longer cost-effective?
Parameter values for the model (Table 2 and Appendix Table 1) were drawn from a study on 
the cost-effectiveness of catch-up vaccination for children and adolescents in China;10 that 
study modeled the effects of chronic hepatitis B infection, but only considered the cost-
effectiveness of current catch-up vaccination efforts (without considering when to stop 
catch-up vaccination), and did not consider costs of vaccination above baseline (thus, the 
optimal catch-up vaccination level for any age group was either 0% or 100%). To model the 
epidemic, we used a slightly more sophisticated model of disease than the model given by 
(1) – (6): we subdivided the infected state I(·) into multiple states in order to more accurately 
represent the costs and health effects of hepatitis B infection (Appendix Figure 1).10 In this 
model of hepatitis B, the basic reproductive number is calculated to be 1.1 which is similar 
to that found in other studies of hepatitis B.64, 65 We used this model of disease when 
solving both P1 and P2. We used a health system perspective and included all lifetime health 
care costs for individuals in the population. The current per capita GDP in China is about 
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$4500,66–68 so an incremental cost-effectiveness ratio between $4,500 and $13,500would be 
considered cost-effective, and a ratio less than $4500 would be considered highly cost-
effective according to WHO criteria.48, 49 In our base case analyses we assumed λ = $4500; 
in sensitivity analysis we considered λ = $13,500 and λ = $0. We considered ages a = 0, 1, 
…, 100 years old and considered a time horizon of T = 100 years. We considered possible 
catch-up vaccination for ages a = 1, …, 19 years old (thus,  for a = 20, …, 100).
5.1 How Many People to Vaccinate Now
Figure 2 shows the net monetary benefit (net value of health benefits minus net health care 
costs) under different willingness-to-pay thresholds for a single individual of age a = 1, …, 
19 calculated using the different incidence estimates described in Section 3; this is the first 
term in the objective function of P2. The net monetary benefit estimates are remarkably 
similar in this example, indicating that a simple estimate of future incidence is sufficient for 
evaluating current catch-up vaccination policies. We note that the net monetary benefits of 
hepatitis B vaccination in China are predicted to be higher using models with static 
incidence than using models with dynamically calculated incidence. China’s hepatitis B 
epidemic is not in a steady state: recent increasing levels of newborn vaccination are 
expected to cause prevalence to drop in the future. Since the dynamic model would capture 
this anticipated lower long-term infection risk to those vaccinated, the dynamic model will 
predict less value to a vaccinated individual than a model using a static prediction of long-
term incidence. Although a static model of incidence may underestimate the value of 
vaccination because it does not incorporate the benefit of preventing secondary infections, a 
static model in this case will overestimate the value of vaccination because it may 
overestimate the infection risk to individuals in the future when prevalence declines. 
Appendix Figures 2a and 2b illustrate this counterintuitive situation by comparing a disease 
with constant prevalence to a disease with declining prevalence such as hepatitis B in China.
Figure 3 shows the optimal fraction of each age group to vaccinate for hepatitis B in China 
as calculated by solving P1 and by solving P2 using the assumption of constant incidence. 
The results are very similar. The optimal solution, obtained by solving P1, is 100% catch-up 
vaccination for all ages 1 through 19. The solution to P2 also calls for 100% catch-up 
vaccination through age 14.In this example, P2 is a good approximation of P1. This is 
because China has a large number of infected individuals who cannot be cured – and thus an 
“infection reservoir” that will remain in the population for a long time.
Figure 4 shows how age and prior vaccination coverage combined can affect the cost-
effectiveness of catch-up vaccination. Values were obtained by solving P2 with each of the 
four different incidence estimates. Each line represents the prior vaccination coverage level 
such that catch-up vaccination costs $4500/QALY gained (Figure 4a), $13,500/QALY 
gained (Figure 4b), or $0/QALY gained (Figure 4c). Figure 4 shows that as the cohort age 
increases, the prior vaccination coverage must be lower for a program to be cost-effective; 
this is because of reduced catch-up vaccination benefit for older individuals. Moreover, for a 
higher willingness to pay per QALY gained (Figure 4b), catch-up vaccination is cost-
effective for higher levels of prior vaccination; and for a lower willingness to pay per QALY 
gained (Figure 4c), catch-up vaccination is cost-effective at lower levels of prior 
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vaccination. As figures 4 and 2 show, for a variety of willingness-to-pay thresholds, the 
policy recommendations about the target level of coverage to provide are invariant to the 
infection risk estimates.
We conducted sensitivity analysis on the recovery rate to see how these general conclusions 
might apply for diseases with shorter infectious periods. If the length of infection is much 
shorter (2–10 years) the results using a static model of incidence versus a dynamic model 
diverge (Appendix Figure 4). Under these conditions, using a dynamic model may be more 
important.
5.2 When to Stop Catch-Up Vaccination
We now examine the problem of how many years into the future to perform catch-up 
vaccination. We first consider programs that would vaccinate children at school entry, either 
at age 5 when entering kindergarten or at age 12 when entering middle school. We assumed 
90% newborn vaccination coverage each year. We assumed different maximum feasible 
levels of catch-up vaccination, ranging from 50% to 100%. We solved P3 with  as 
calculated by P1 (exact numerical solution) and then as calculated by P2 (approximate 
numerical solution). The solutions obtained using these two methods were identical, and 
called for the maximum feasible level of catch-up vaccination each year until it is no longer 
cost-effective. Figure 5a shows that, if just 5-year-olds are vaccinated, catch-up vaccination 
must continue for about 71 years if 100% catch-up coverage can be achieved, and for 77 
years if only 50% coverage can be achieved. Similarly, if just 12-year-olds are vaccinated, 
catch-up vaccination must continue for 67 years if 100% coverage can be achieved, and for 
73 years if only 50% coverage can be achieved.
We next consider a program that would provide catch-up vaccination to children at both 
points of school entry, ages 5 and 12. Figure 5b shows that the number of years for which 
catch-up vaccination of 5-year-olds is cost-effective is unchanged, but catch-up vaccination 
for 12-year-olds is discontinued sooner than when there was no 5-year-old vaccination. 
When 5-year-olds also receive catch-up vaccination, catch-up vaccination of 12-year-olds 
continues for 11 years if 100% coverage can be achieved, and for 66 years if only 50% 
coverage can be achieved.
The model can also be used to determine the “best case” scenario for catch-up vaccination 
among children, which would occur if all eligible children were to receive 100% catch-up 
vaccination. Figure 6a shows the solution to P3 assuming that all eligible children ages 1 
through 19 can be reached by catch-up vaccination, and that the current newborn 
vaccination level of 90% continues each year. Those solutions call for 100% vaccination 
coverage for most ages until catch-up vaccination is no longer cost-effective. At older ages, 
the catch-up vaccination program covers many of the children in the first few years, so 
further catch-up vaccination is no longer cost-effective because the program creates high 
levels of immunity in the population (and thus more wasted re-vaccinations). However, for 
children age 1, the catch-up vaccination program is still cost-effective because newborn 
coverage still leaves many susceptible children (with fewer wasted re-vaccinations), and 
younger children still have much to benefit from vaccination. Figure 6a also shows the cases 
in which the maximum feasible catch-up vaccination coverage in any year is at most 75% or 
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50%. With these lower coverage levels, catch-up vaccination must be continued for several 
more years for children of school age, and for many more years for preschool age children.
In China, remote rural regions have significantly lower birth-dose vaccination coverage than 
urban areas.4, 58 Figure 6b shows the solution to the catch-up vaccination problem for a 
region in which only 75% newborn vaccination coverage is achieved, and for the cases of 
50%, 75%, and 100% maximum achievable catch-up vaccination coverage in each age 
group. Compared to the case of 90% newborn coverage, it is cost-effective to provide catch-
up vaccination for more years in the future and for older children.
We conducted sensitivity analysis on the rate of disease transmission, the awareness of 
serostatus, the discount rate, length of infection, and threshold cost-effectiveness ratio. If the 
rates of disease transmission are significantly lower, the catch-up vaccination program 
becomes less valuable and would not be continued as long, but the different infection risk 
estimates would still lead to similar conclusions (Appendix Figure 5). If more individuals 
are aware of their serostatus, a catch-up vaccination program would be more valuable 
because unnecessary vaccination would not be performed (Appendix Figure 6), and if the 
discount rate used were lower (higher), the program would be more (less) valuable and 
would be continued a longer (shorter) time in the future (Appendix Figure 7). If the average 
length of infection were shorter than 10 years and if catch-up vaccination were given to all 
children ages 1–19, then it would not be valuable to continue catch-up vaccination as long 
because the disease could be more quickly controlled (Appendix Figure 8). Finally, if the 
threshold cost-effectiveness ratio is higher (lower), the length of time in the future to 
continue catch-up vaccination is slightly longer (shorter) (Appendix Figure 9).
6. Discussion
Catch-up vaccination can be a cost-effective (or even cost-saving) health intervention, but 
catchup vaccination programs can become less cost-effective as newborn vaccination rates 
increase. Our models can be used to determine the optimal fraction of each age group to 
vaccinate, and when to stop such catch-up vaccination. Such information can help decision 
makers make the best use of limited health care resources now, and can assist with future 
public health planning.
We have shown that simple analyses, which ignore changes in future disease incidence 
caused by catch-up vaccination, can provide good solutions to the catch-up vaccination 
problem. This is particularly true for diseases such as hepatitis B; that is, incurable diseases 
with long infectious periods for which there is a stable infection reservoir in the population. 
Our simple model of when to stop catch-up vaccination (P3 with the approximate 
subproblem P2 and a simple estimate of constant future disease incidence) could be readily 
used by decision makers, as such a model requires significantly less data than a full dynamic 
model and can easily be implemented in a spreadsheet. The simple model requires estimates 
of vaccination cost as a function of how many people are vaccinated (CVa(xa)); net present 
health costs and QALYs for susceptible and immune individuals of a given age (Ha,R, Ha,S, 
Ca,R, and Ca,S, which can be estimated from a Markov or other model); the number of 
infected people in the population by age (Ia(0)); the total population size (N(0)); and current 
Hutton and Brandeau Page 13













disease incidence in different age groups (ia(0)). Data to support estimation of these 
quantities are typically available to public health decision makers. The simple model 
provides insights which are likely to also hold when more detailed models of disease are 
used.
These results complement prior research examining vaccination programs using static and 
dynamic models of infection. Edmunds et al.38 and Brisson and Edmunds39 note that 
constant-force-of-infection models may be appropriate if mass immunization does not 
substantially alter herd immunity. We have found this to be the case for catch-up vaccination 
for a disease with a large, stable infection reservoir.
We illustrated our ideas using the example of hepatitis B catch-up vaccination in China. We 
showed that, even with 90% newborn vaccination coverage, it is still cost-effective to 
provide catch-up vaccination to preschool age children for decades into the future, 
particularly if the catch-up vaccination programs cannot reach all susceptible children. If 
only selected groups can be reached by catch-up vaccination, or if newborn vaccination 
coverage is lower than 90%, it is cost-effective to perform catchup vaccination even longer.
Our analysis has several limitations. Our dynamic model of infection (which we calibrated 
to observed hepatitis B incidence in the Chinese population for our example) assumes 
homogenous mixing. Since this is unlikely to be the case, the quantitative results should be 
interpreted with caution if used to inform decision making. For some diseases such as 
hepatitis B, there is little hard evidence on how population mixing affects disease spread 
other than in limited instances such as transmission from mother to child. However, it may 
be possible that a population exhibits preferential mixing patterns where certain age groups 
have higher infectious contact with certain other age groups: for example, young adults 
could preferentially transmit an infection through sexual contact with other young adults, or 
young children could preferentially transmit a bloodborne infection to other children through 
childhood cuts and scrapes. It is straightforward to modify our dynamic model given by (1) 
– (6) to incorporate preferential mixing and it is straightforward to write an expression for 
incidence in each age group (similar to (12)). If individuals mix preferentially with similar 
age groups, catch-up vaccination programs that target younger high-risk individuals could 
reduce the epidemic prevalence more quickly because these young individuals will be the 
most important reservoir infecting other young individuals in the future. The cutoff and age-
out incidence estimates in Section 3.3 can be modified for the case of preferential mixing by 
replacing the assumption that the total population size is constant with the assumption that 
the number of people in each age group is constant. Additionally, our mathematical 
presentation in equations (1) – (6) used an SIR model, with the Infected state representing 
all infected individuals. A more detailed SICR model incorporating an additional Carrier 
state could also be used if it is desired to explicitly model transient versus chronic infection. 
Finally, our model does not include waning vaccine immunity. Although the assumption of 
lifelong immunity is likely appropriate for hepatitis B,69, 70 waning immunity may be 
important to incorporate for other diseases. Waning immunity would lead to a longer 
continuation of catch-up vaccination efforts. Future analyses could incorporate waning 
immunity into the model.
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Many countries also face a high burden of disease from hepatitis B. For example, Vietnam 
has chronic hepatitis B prevalence and death rates that are approximately twice as high as in 
China.62, 71 Our models could be used to determine cost-effective catch-up vaccination 
levels for these settings. Our methods may also be applicable to other long-term chronic 
infectious diseases. For example, human papillomavirus (HPV) is an incurable, vaccine-
preventable infection that may have a long infectious period. Thus, as for hepatitis B, a 
catch-up vaccination program is unlikely to have a major impact on the number of people 
currently infected, which means that it is unlikely to have a major impact on the infection 
risk. However, because the major mode of transmission of HPV is sexual, a dynamic 
transmission model with preferential mixing patterns might be more accurate than the model 
given by (1) – (6).
Our sensitivity analyses suggest that static models may be acceptable for evaluating catch-
up vaccination programs that are supplemental and unlikely to have a large impact on the 
course of the epidemic. For an epidemic that is not in a steady state or when the catch-up 
vaccination program is likely to have an appreciable impact on the overall course of the 
epidemic, then a dynamic model may be needed to provide more accurate results.
No vaccines currently exist for human immunodeficiency virus (HIV) and hepatitis C virus 
although a number of trials for potential vaccines against these diseases are currently 
underway.72, 73 If and when vaccines are developed for these diseases, the dissemination of 
these vaccines would likely follow a path similar to that of the hepatitis B vaccine: first to 
high-risk groups, then to young age groups and, finally, catch-up vaccination. If the disease 
spread is generalized (not concentrated in certain risk groups), then an analysis such as ours 
might be helpful once vaccine production levels are sufficient to allow for catch-up 
vaccination.
Newborn vaccination rates are insufficient to protect children from many diseases, making 
catchup vaccination an important and cost-effective health intervention. We have shown that 
simple models may be sufficient to give policymakers insight into the appropriate levels of 
catch-up vaccination and guidance as to how long catch-up vaccination should be continued. 
Such models can be especially helpful for diseases such as hepatitis B that are endemic and 
have a large infection reservoir.
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APPENDIX
Calculation of Optimal Vaccination Level
We characterize the optimal level of vaccination , for P2, and show how it varies as a 
function of the newborn vaccination level, cohort age, disease incidence, and vaccination 
cost. The first two terms in (11) are positive (by assumption, catch-up vaccination generates 
an incremental health benefit to the person vaccinated, and reduces that person’s future 
health care costs) and increasing linearly in xα, and the term CVα(xα) is nonnegative, 
convex, and nondecreasing in xα. Thus, the objective function of P2 is concave in xα and has 
the following optimal solution:
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The optimal vaccination level may be zero, , or an interior point solution, 
. We note that if fα(xα)=0 (no costs above baseline), then  or . 
Appendix Figure 3 shows the case of an interior solution.
Given the above expression for the optimal vaccination level, it is straightforward to 
establish the following.
Optimal Vaccination Level
The optimal vaccination level obtained by solving P2 is:
i. nonincreasing in the newborn vaccination level x0(·) (i.e., the level of prior 
immunity);
ii. nonincreasing in cohort age α;
iii. nondecreasing in the disease incidence ia(t); and
iv. nonincreasing in vaccination cost CVα(xα).
As the newborn vaccination level x0((·) increases, the number of individuals who are 
immune but unaware of their immunity Ra(0) uR,a will increase (because of our assumption 
that a constant fraction of immune individuals are unaware of their disease status); thus, for 
any given vaccination level, the fraction of vaccinations given to individuals who do not 
need it will increase. The benefits of catch-up vaccination are driven by the risk of infection 
and age. Benefits of catch-up vaccination are nonincreasing with the age of those vaccinated 
because younger children will live longer and will be exposed to more opportunities to 
become infected than adults: (Ha,R − Ha,S) and (Ca,R − Ca,S) will have nonincreasing 
differences with age. Thus, the optimal vaccination level is higher (or at least not lower) for 
younger age groups than for older age groups. A higher risk of infection will increase the 
monetary benefits of a vaccination program by increasing health benefits that accrue to 
successfully vaccinated individuals (Ha,R − Ha,S) and increasing the health savings for those 
individuals (Ca,R − Ca,S); thus, a higher risk of infection leads to a higher cost-effective level 
of catch-up vaccination. Finally, if the vaccination cost CVα(xα) increases, the optimal 
vaccination level cannot increase.
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Hepatitis B Model for China
The model of hepatitis B used in our example analysis includes additional health states for 
the “infected” health state, as shown in Appendix Figure 1. Appendix Table 1 provides 
values for parameters used in the model.
To estimate incidence of acute hepatitis B infection in unprotected individuals, we evaluated 
how prevalence has evolved over time in the population of children in China. We first 
calculated what we would expect prevalence of chronic disease to be at birth given expected 
chronic disease prevalence of 5% at birth without vaccination85 and using observed birth-
dose vaccination coverage and vaccine efficacy. We then used this along with information 
about the likelihood of acute infections becoming chronic to estimate the number of chronic 
infections and probability of immunity to hepatitis B in early childhood (ages 1–4 and 5–
14). By varying the incidence of acute infection, we could see what incidence level would 
most closely match the observed prevalence of chronic infection and immunity. Knowing 
the incidence of acute infection and current prevalence in the entire population of China 
(7.4%) enabled us to calculate the rate of contact that is sufficient to transmit the infection, 
β. These calculations matched disease prevalence and immunity observed in the Chinese 
population approximately but not exactly, so we varied the value of β widely in sensitivity 
analysis.
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Appendix Figure 1. 
Diagram of model of hepatitis B infection and progression*. This model is used in both P1 
and P2. It is used to calculate the dynamic health effects and costs in P1 and used to 
calculate the long-term health effects and costs, Ha,d and Ca,d for P2.
* ALT = alanine aminotransferase. Circles represent health states. Lines represent transitions 
between those states. Although not shown, individuals with decompensated cirrhosis can 
also have other complications such as variceal bleeding, ascites, or encephalopathy. 
Additionally, the model is age-structured, so each disease state is indexed by age a = 1, …, 
A and at each time step individuals of age a transition to a disease state for individuals age a
+1.
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Appendix Figure 2. 
Projected incidence starting in a steady state epidemic (Appendix Figure 2a) and a declining 
epidemic (Appendix Figure 2b), under the status quo and in the presence of catch-up 
vaccination. The “northwest-southeast” diagonal lines represent the benefit projected using a 
static model. The “northeast-southwest” diagonal lines represent the benefit projected using 
the dynamic model.
Appendix Figure 2a: Projected incidence starting in a steady state epidemic. The reduction 
in incidence projected using the dynamic model is greater than that projected using a static 
model.
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Appendix Figure 2b: Projected incidence starting in a declining epidemic. The reduction in 
incidence projected using the dynamic model is smaller than that projected using a static 
model.
Appendix Figure 3. 
Example of the form of the benefits, costs and net monetary benefit of vaccinating a fraction 
xa of individuals in age group a.
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Appendix Figure 4. 
Hepatitis B example: Sensitivity analysis of net monetary benefit for a single susceptible 
individual as a function of rate of recovery from chronic hepatitis B infection.
Appendix Figure 4a: 1% annual recovery (and immunity) from chronic infection.
Appendix Figure 4b: 5% annual recovery (and immunity) from chronic infection.
Appendix Figure 4c: 10% annual recovery (and immunity) from chronic infection.
Appendix Figure 4d: 50% annual recovery (and immunity) from chronic infection.
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Appendix Figure 5. 
Hepatitis B example: Results for a lower transmission scenario (β at 1/10 of its initial value 
and the risk of mother-to-child transmission halved).
Appendix Figure 5a: Vaccination of 5-year-olds or 12-year-olds
Appendix Figure 5b: Vaccination of both 5-year-olds and 12-year-olds
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Appendix Figure 6. 
Hepatitis B example: Sensitivity to changes in awareness of hepatitis B serostatus.
Appendix Figure 6a: 90% birth coverage, with 50% aware of infection and 75% aware of 
serostatus
Appendix Figure 6b: 90% birth coverage, with 95% aware of infection and 95% awareness 
of serostatus
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Appendix Figure 7. 
Hepatitis B example: Sensitivity to changes in discount rate.
Appendix Figure 7a: 90% birth coverage, with 0% discount rate
Appendix Figure 7b: 90% birth coverage, with 5% discount rate
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Appendix Figure 8. 
Hepatitis B example: Impact of rate of recovery from chronic hepatitis B infection on length 
of time to continue a catch-up vaccination program for all children ages 1–19.
Appendix Figure 9. 
Hepatitis B example: Impact of willingness-to-pay threshold on the length of time to 
continue a vaccination program for both 5-year-olds and 12-year-olds.
Appendix Table 1




Compliance with vaccine intervention 70% Assumed
Percent chronically infected who are aware of infection1 50% 83, 84
Percent aware who receive medical management 50% Assumed
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Chronic infections that have elevated ALT 2.0% Assumed
Already immune (given no chronic infection) 50% Assumed
Aware of immunity (previous vaccination) 75% Assumed
Protected by three doses of HBV vaccine 95% 81, 82, 86
Annual voluntary vaccination 0.5% Assumed
Acute Infection
Annual acute HBV infection incidence 1000/100,000 56, 87–91
Asymptomatic acute infections 90% 80, 92–95
Symptomatic acute infections that require hospitalization 12% 80, 92, 93
Hospitalized cases that are fulminant 4% 80, 92, 93
Fulminant cases that result in death 70% 80, 92, 93
Disease Progression parameters (annual probabilities)
Normal ALT to elevated ALT2 0.15% 96
Normal ALT to HCC 0.34% 98
Durable virologic response while on treatment 15% 79, 99–102
Chronic HBV infection with elevated ALT to compensated cirrhosis 3.8% 76, 79
Chronic HBV infection with elevated ALT to HCC 1.5% 76, 79
Durable response relapse to elevated ALT 7% 79, 103, 104
Durable response to HCC 0.34% 98
Compensated cirrhosis to decompensated cirrhosis 7% 76, 79
Mortality from compensated cirrhosis 4.8% 76, 79
Mortality from decompensated cirrhosis 17.3% 76, 79
Cirrhosis to HCC 3.3% 76, 79, 105
Cirrhosis to cirrhosis with ascites 68% 79
Cirrhosis to cirrhosis with variceal bleeding 14.6% 79
Cirrhosis to cirrhosis with encephalopathy 10% 79
Receiving a liver transplant while in decompensated cirrhosis 1.5 % 76, 79, 106–108
Mortality from HCC 40.0% 76, 79, 109, 110
Mortality from HCC while on medical management (due to early detection) 20% 110
Receiving a liver transplant while in HCC 0.1% 76, 79, 108, 111–115
Mortality first year after liver transplantation 15% 76, 79
Mortality second and subsequent years after liver transplantation 1.5% 76, 79
Costs ($)
Vaccine costs
 Vaccine (per dose) 0.34 15, 74, 1163
 Vaccine administration (per dose) 0.60 116
Liver transplantation cost 30,000 76, 77
Annual treatment costs
 Fraction of patients on drug therapy while in durable response4 50% Assumed
 Drugs 2000 76, 78
 Regular health monitoring 250 75, 77
 Cirrhosis 2000 75–77
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 Ascites 2500 75–77
 Encephalopathy 2500 75–77
 Variceal hemorrhage 2500 75–77
 HCC 5000 75–77
 Transplantation followup 3000 76
Annual normal health care costs 118 117
Discount rate 3% 118
Quality Multipliers
Acute HBV infection 0.94 80
Chronic HBV infection, normal ALT 1.00 80, 99
Chronic HBV infection, elevated ALT 0.99 76, 80, 99
Durable response 1.00 79
Compensated cirrhosis 0.80 76, 79, 99
Decompensated cirrhosis 0.60 76, 79, 99
HCC 0.73 76, 79, 99
Liver transplant 0.86 76, 79, 99
HBV – hepatitis B virus; ALT – alanine aminotransferase
1
Percentage of all chronically infected individuals who are aware of their infection
2
This value was estimated from 96, and then calibrated to yield approximately 25% mortality from untreated liver 
disease 86, 97.
3
Personal communication with physicians in China
4
Some therapies are discontinued if the therapy suppresses the virus. This parameter is the fraction of patients who 
continue on drug therapy after the therapy has suppressed the virus into a “durable response.”
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Schematic of age-structured SIR model, showing transitions that occur from time period t to 
time period t+1. The model incorporates ages a = 0, 1, …, A and time periods t = 0, 1, …, T.
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Hepatitis B example: Effect of different incidence estimates on the net monetary benefit of 
vaccinating a single susceptible individual, the first two terms in the objective function of P2 
(which excludes secondary infections). The top sets of lines are for willingness-to-pay 
values of $13500 per QALY, the second set of lines are for willingness-to-pay values of 
$4500 per QALY, and the bottom set of lines are for willingness-to-pay values of $0 per 
QALY.
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Hepatitis B example: Optimal fraction of each age group to vaccinate, obtained by solving 
P1 (which includes secondary infections) and P2 (which excludes secondary infections) 
using the assumption of constant incidence and assuming λ = $4500/QALY.
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Hepatitis B example: Policy space of cost-effectiveness for various ages and levels of prior 
vaccination coverage for different incidence estimates, obtained by solving P2 (which 
excludes secondary infections) with λ = $4500/QALY (Figure 4a), $13,500/QALY (Figure 
4b), and $0/QALY (Figure 4c). Each line represents the prior vaccination coverage level 
such that catch-up vaccination costs $4500/QALY gained (Figure 4a), or $13,500/QALY 
gained (Figure 4b), or $0/QALY gained (Figure 4c). Areas above the lines are regions in 
which the catch-up vaccination intervention is not cost-effective and areas below the lines 
are regions in which the intervention is cost-effective.
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Figure 4a: Willingness-to-pay $4500/QALY gained
Figure 4b: Willingness-to-pay $13500/QALY gained
Figure 4c: Willingness-to-pay $0/QALY gained
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Hepatitis B example: Number of years for which it is cost-effective to perform catch-up 
vaccination for hepatitis B in children ages 5 and 12, obtained by solving P3, and assuming 
λ = $4500/QALY. The newborn vaccination rate is assumed to be 90%. The optimal 
solution is the maximum allowable level of catch-up vaccination each year until it is no 
longer cost-effective. We consider 50%, 75%, 90%, and 100% maximum achievable 
vaccination coverage. Figure 5a shows two cases, 5-year-olds vaccinated or 12-year-olds 
vaccinated, and Figure 5b shows the case of a joint vaccination program that vaccinates both 
5-year-olds and 12-year-olds.
Figure 5a: Vaccination of 5-year-olds or 12-year-olds
Figure 5b: Vaccination of both 5-year-olds and 12-year-olds
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Hepatitis B example: Number of years for which it is cost-effective to perform catch-up 
vaccination for hepatitis B in children age 19 and younger, obtained by solving P3, and 
assuming λ = $2500/QALY. The newborn vaccination rate is assumed to be 90% in Figure 
6a, and 75% in Figure 6b. Each line represents a different possible x* (fraction vaccinated 
each year): the optimal solution is 100% catch-up vaccination of age groups each year until 
it is no longer cost-effective; the figure also shows the case of lower vaccination levels (50% 
and 75%).
Figure 6a: 90% newborn vaccination coverage
Figure 6b: 75% newborn vaccination coverage
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t Time index; t = 0, 1, …, T
a Index for age groups; a = 0, 1, …, A; a = 0 represents newborns
xa(t) Fraction of eligible individuals of age a vaccinated during time period t, ; x0(t) represents vaccination at 
birth
Sa(t) Number of susceptible individuals in age group a in time period t; Sa(0) = Sa,0, a > 0
Ia(t) Number of infected individuals in age group a in time period t; Ia(0) = I a,0, a > 0
Ra(t) Number of immune individuals in age group a in time period t; Ra(0) = R a,0, a > 0
Na(t) Total number of individuals in age group a in time period t; Na(t) = Sa(t) + Ia(t) + Ra(t)
N(t)
Total number of individuals in the population in time period t; n
βa
Disease sufficient contact rate for individuals of age a (rate of contact between susceptible individuals of age a and infected 
individuals that is sufficient to transmit the infection)
ia(t) Risk of infection to a susceptible individual of age a in time period t, 0 ≤ ia(t) ≤ 1
ϕa Fertility rate for individuals in age group a (averaged across males and females)
p0 Chance that an unvaccinated child is infected perinatally and develops chronic infection
pa Chance that an acute infection in a person of age a > 0 will become a chronic infection
ν Rate of recovery from the chronic infection, ν ≥ 0
μa,d Fraction of individuals of age a in disease state d who die in any time period
e Effectiveness of the vaccine at inducing immunity in a susceptible individual
uI,a Fraction of infected individuals in age group a who are unaware of their infection
uR,a Fraction of immune individuals in age group a who are unaware of their immunity
cad Health care cost per unit time for a person of age a in disease state d
qad Quality-of-life multiplier for a person of age a in disease state d
Ca,d Expected net present health care costs for a person of age a in disease state d
Ha,d Expected net present health effects measured in quality-adjusted life years (QALYs) for a person of age a in disease state d
F Fixed cost of the catch-up vaccination program; F ≥ 0
cv Baseline marginal cost to vaccinate one person
fa(xa(t))
Cost above baseline per person vaccinated, as a function of the fraction xa(t) of age group a vaccinated; assumed to be 
nonnegative, nondecreasing, and convex in xa(t)
CVa(xa(t)) Total cost of vaccinating a fraction xa(t) of individuals in age group a
λ Monetary value of health effects
r Discount rate for costs and health benefits
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Table 2
Key parameter values for numerical example of hepatitis B in China.
Parameter Base Value Source
Newborn vaccination coverage, x0 (t) 90% 4, 58
Maximum allowable catch-up vaccination level, , a = 1, …, 19
1 Assumed
Fixed cost of vaccination program, F $0 Assumed
Baseline marginal cost of vaccination, cv $2.82 10, 74
Cost of vaccination above baseline, fa(xa) 0 for xa <0.5
cv(2xa−1) for xa ≥ 0.5
50–53
Monetary value of a year of full health, λ $4500/QALY Based on per capita GDP66–68
Population size, N(0) 1.3 billion 68
Health care cost per year, ca,d $118–$5,000* 10, 75–78
Quality multiplier for health states, qa,d 0.6–1.0* 10, 33, 76, 79, 80
Vaccine effectiveness, e 0.95 10, 44, 81, 82
Fraction of infected who are unaware of their infection, uI, a 50% 10, 83, 84
Fraction of immune who are unaware of their immunity, uR,a 25% 10
Sufficient contact rate, βa 0.135 Based on calculations from 10, 58
Discount rate, r 3% 18
*
Costs vary by disease state (see Appendix Figure 1), from $118 for healthy individuals to $5,000 for those with liver cancer. Quality multipliers 
vary from 0.6 for those with decompensated cirrhosis to 1.0 for healthy individuals. Details are provided in Appendix Table 1.
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